Table 2.
Medication | Mechanism of action |
---|---|
2a) Oral medications | |
Trihexyphenidyl | Anticholinergic |
Baclofen | GABA-B receptor agonist |
Benzodiazepines | GABA enhancer |
Lorazepam | |
Diazepam | |
Clonazepam | |
Carbidopa-levodopa | Metabolic precursor of dopamine |
Muscle relaxants | |
Cycloben-zaprine | Skeletal muscle relaxant |
Metaxalone | Skeletal muscle relaxant |
Carisoprodol | Skeletal muscle relaxant |
Methocar-bamol | Skeletal muscle relaxant |
Orphenadrine | Skeletal muscle relaxant |
Chlorzoxa-zone | Skeletal muscle relaxant |
Sodium oxybate | Salt of gamma-hydroxybutyric acid |
Tetrabenazine | Vesicular monoamine transporter 2 inhibitor. Weak D2 receptor antagonist |
Clozapine | Dopamine receptor antagonist, mainly D4 |
Carbamazepine | Anticonvulsant, sodium channel inhibitor |
Oxcarbazepine | Anticonvulsant, sodium channel inhibitor |
Zolpidem | Non-benzodiazepine hypnotic, affinity for GABA-benzodiazepine subtype receptor BZ1 (ω1) |
Pregabalin | Calcium channel inhibitor |
2b) Non-pharmacologic therapies | |
Botulinum toxin | |
OnabotulinumtoxinA | |
AbobotulinumtoxinA | |
IncobotulinumtoxinA | |
RimabotulinumtoxinB | |
Surgery | |
Deep brain stimulation | |
Ablative procedures | |
Selective peripheral denervation | |
Intrathecal baclofen | |
Intraventricular baclofen | |
Oculofacial plastic procedures | |
Other therapies | |
Physical therapy | |
Braces | |
Eyelid crutches | |
Dental devices | |
Transcranial magnetic stimulation | |
Transcranial alternating current stimulation |
GABA = gamma aminobutyric acid